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Functional and structural protein analysisß-Ureidopropionase is the third enzyme of the pyrimidine degradation pathway and catalyzes the conversion
of N-carbamyl-ß-alanine and N-carbamyl-ß-aminoisobutyric acid to ß-alanine and ß-aminoisobutyric acid,
ammonia and CO2. To date, only ﬁve genetically conﬁrmed patients with a complete ß-ureidopropionase de-
ﬁciency have been reported. Here, we report on the clinical, biochemical and molecular ﬁndings of 11 newly
identiﬁed ß-ureidopropionase deﬁcient patients as well as the analysis of the mutations in a three-dimensional
framework. Patients presented mainly with neurological abnormalities (intellectual disabilities, seizures, abnor-
mal tonus regulation, microcephaly, and malformations on neuro-imaging) and markedly elevated levels of
N-carbamyl-ß-alanine and N-carbamyl-ß-aminoisobutyric acid in urine and plasma. Analysis of UPB1,
encoding ß-ureidopropionase, showed 6 novel missensemutations and one novel splice-site mutation. Het-
erologous expression of the 6 mutant enzymes in Escherichia coli showed that all mutations yielded mutant
ß-ureidopropionase proteins with signiﬁcantly decreased activity. Analysis of a homology model of human
ß-ureidopropionase generated using the crystal structure of the enzyme from Drosophila melanogaster indi-
cated that the point mutations p.G235R, p.R236W and p.S264R lead to amino acid exchanges in the active
site and therefore affect substrate binding and catalysis. The mutations L13S, R326Q and T359M resulted
most likely in folding defects and oligomer assembly impairment. Twomutationswere identiﬁed in several unre-
lated ß-ureidopropionase patients, indicating that ß-ureidopropionase deﬁciency may be more common than
anticipated.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
In most organisms, the pyrimidine bases uracil and thymine are
degraded by a three-step reaction sequence of the reductive, Laboratory Genetic Metabolic
The Netherlands. Tel.: +31 20
P. van Kuilenburg).
l rights reserved.pyrimidine degradation pathway (Fig. 1) [1]. Dihydropyrimidine
dehydrogenase (DPD, EC 1.3.1.2) is the initial and rate-limiting en-
zyme, catalyzing the reduction of uracil and thymine to 5,6-dihy-
drouracil and 5,6-dihydrothymine, respectively. The second step
is catalyzed by dihydropyrimidinase (EC 3.5.2.2) and consists of a re-
versible hydrolysis of the dihydropyrimidines. Finally, the resulting
N-carbamyl-ß-alanine and N-carbamyl-ß-aminoisobutyric acid are
converted in the third step to ß-alanine and ß-aminoisobutyric acid,
ammonia and CO2 by ß-ureidopropionase (EC 3.5.1.6).
Fig. 1. Catabolic pathway of the pyrimidine bases uracil and thymine. The genes encod-
ing the enzymes of the pyrimidine degradation pathway are given in parenthesis.
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an important route for the synthesis of ß-alanine and ß-aminoisobutyric
acid in human beings [2,3]. ß-Alanine is a structural homologue of γ-
aminobutyric acid and glycine, which are the major inhibitory neuro-
transmitters in the central nervous system. ß-Alanine itself has been
suggested to be involved in synaptic transmission and has been
shown to regulate dopamine levels [4,5]. ß-Aminoisobutyric acid is a
partial agonist of the glycine receptor and stimulates the secretion of
leptin and fatty acid oxidation [6–8]. Thus, an altered homeostasis of
these ß-amino acids might underlie some of the clinical abnormalities
encountered in patients with a pyrimidine degradation defect [9,10].
To date, more than 75 patients have been described with a DPD
deﬁciency and 28 patients with a dihydropyrimidinase deﬁciency
[10,11]. In contrast, only 5 genetically conﬁrmed patients with a ß-
ureidopropionase deﬁciency have been described until now and the
clinical, biochemical and genetic spectrum in patients with a ß-
ureidopropionase deﬁciency is still largely unknown [12,13]. The ß-
ureidopropionase gene (UPB1) gene has been mapped to chromosome
22q11.2 and consists of 11 exons spanning approximately 20 kb of
genomic DNA [14]. The cDNA coding for human ß-ureidopropionase
contains an open reading frame of 1152 nucleotides, corresponding to
a protein of 384 amino acids with a calculated molecular weight of
43,158 Da [14].ß-Ureidopropionase has been puriﬁed and characterized from var-
ious eukaryotic species including rat, bovine, human and Drosophila
melanogaster [15–18]. Based on comparison of primary structures
and phylogenetic analysis, the eukaryotic ß-ureidopropionases can
be assigned to two subfamilies [19]. One subfamily consists of mainly
fungal enzymes, while higher eukaryotic ß-ureidopropionases consti-
tute the second subfamily. Although functionally related, the members
of the distinct subfamilies show a high degree of structural diversity
[18–20]. The amino acid sequence of human ß-ureidopropionase shares
63% identity with the enzyme from D. melanogaster (DmβUP), whose
crystal structurewas recently determined [18]. Its subunit shows signif-
icant similarity to that of other enzymes of the nitrilase superfamily to
which also human ß-ureidopropionase belongs [21].
Here, we report on the clinical, biochemical and molecular ﬁndings
of 11 newly identiﬁed patients with a complete ß-ureidopropionase de-
ﬁciency and compared these to the 5 previously characterized patients.
We report the functional and structural consequences of the mutations
at the protein level using a homology model that was generated based
on the crystal structure of recombinant DmβUP.
2. Materials and methods
2.1. Patients
The patients were collected in Germany, Sweden, Egypt, China and
Japan. Criteria to test for a metabolic disorder in general or speciﬁcally
for a disturbed purine/pyrimidine metabolism vary in the various
countries. In general patients are tested for a metabolic disorder if pa-
tients show developmental delay, neurological manifestations (such
as ataxia or dystonia), enlarged liver and spleen or gingiva hyperpla-
sia, skeletal dysostosis and if patients have prolonged signs and
symptoms of the hematological, immunological, ophthalmological
and gastrointestinal systems. This indicates that patients with a dif-
ferent phenotype will not be tested and will not be detected, which
creates a bias in symptomatology. Based on the above indication, 9
patients were identiﬁed in whom a ß-ureidopropionase deﬁciency
was likely. Subsequent analysis of family members of the affected pa-
tients revealed another 2 probably affected persons. Samples of all
patients were forwarded to the Laboratory for Genetic Metabolic Dis-
eases in Amsterdam for further analysis.
2.2. Analysis of pyrimidines in body ﬂuids
Concentrations of uracil, thymine, dihydrouracil, dihydrothymine,
N-carbamyl-ß-alanine and N-carbamyl-ß-aminoisobutyric acid in
urine, plasma and CSF were determined using reversed-phase HPLC
combined with electrospray tandem mass spectrometry [22,23].
2.3. PCR ampliﬁcation of coding exons of UPB1 and DNA sequencing
DNA was isolated from EDTA blood by standard procedures. Exons
1–11 of UPB1 and their ﬂanking sequences were ampliﬁed using the
primer sets, as described before [12]. Ampliﬁcation was carried out
in 25 μl reaction mixtures containing 20 mM Tris/HCl pH 8.4, 50 mM
KCl, 1.5 mM MgCl2, 0.4 μM of each primer, 0.2 mM dNTPs and 0.02 U
of Platinum Taq polymerase. After initial denaturation for 5 min at
95 °C, ampliﬁcation was carried out for 8 cycles (30 s 95 °C, 30 s 55 °C,
60 s 72 °C) and 27 cycles (30 s 95 °C, 90 s 72 °C) with a ﬁnal extension
step of 10 min at 72 °C. PCR products were separated on 1.5% agarose
gels, visualized with ethidium bromide treated with exoSAP-IT and
used for direct sequencing.
Sequence analysis of genomic fragments ampliﬁed by PCR and ex-
pression plasmids was carried out on an Applied Biosystems model
3730 automated DNA sequencer using the Big dye-terminator method
(Perkin Elmer Corp., Foster City, CA, USA). UPB1 sequence of patients
1098 A.B.P. van Kuilenburg et al. / Biochimica et Biophysica Acta 1822 (2012) 1096–1108was compared to that observed in controls and the reference sequence
of UPB1 (Ref Seq NM_016327.2).
2.4. Expression and activity analysis of ß-ureidopropionase in
Escherichia coli
To obtain an expression plasmid containing wild-type human ß-
ureidopropionase cDNA (pSE420-ßUP), the NcoI–NaeI insert of a
plasmid comprising the complete coding region of the human ß-
ureidopropionase gene was subcloned into the pSE420 vector [14].
Mutations were introduced into the human ß-ureidopropionase se-
quence using the megaprimer technique and the resulting mutant
genes were cloned into the pSE420 vector, essentially as described
before [12]. Resulting clones were sequenced completely to verify
the presence of the mutation and to exclude the presence of random
mutations introduced by PCR artifacts. Expression plasmids were in-
troduced into the E. coli strain BL21(DE3). A 25 ml LB broth culture,
supplemented with 50 μg/ml ampicillin, was inoculated with 250 μl
of an overnight preculture grown in LB broth. Cells were grown for 3 h
at 37 °C and induction was performed by the addition of isopropyl-ß-
D-thiogalactoside to a ﬁnal concentration of 0.4 mM. Cells were sedi-
mented after 3 h and washed twice with phosphate-buffered saline
(PBS). The cell pellet was frozen at −80 °C and subsequently resus-
pended in 300 μl isolation buffer (35 mM potassium phosphate pH 7.4
and 2.5 mMMgCl2) and lysed by sonication. The crude lysate was cen-
trifuged at 18,000×g at 4 °C for 15 min and the resulting supernatant
was stored at−80 °C.
The activity of ß-ureidopropionase was determined at 37 °C in a
standard assay mixture containing an aliquot (8–10 μl) of cell superna-
tant, 200 mMMOPS (pH 7.4), 1 mMdithiothreitol and 500 μM [14C]-N-
carbamyl-ß-alanine [24]. Separation of radiolabeled N-carbamyl-
ß-alanine from radiolabeled ß-alanine was performed isocratically
(50 mM NaH2PO4, pH 4.5, at a ﬂow rate of 1 ml/min) by reversed-
phase HPLC on an Aqua C18 column (250×4.6 mm, 5 μm particle size,
Phenomenex, Torrance, CA) and a guard column (Securityguard C18,
4×3.0 mm ID, Phenomenex, Torrance, CA) with on-line detection of
the radioactivity.
2.5. Western blot analysis
Supernatants (10 μg) were fractionated on a 8% (w/v) SDS-
polyacrylamide gel and transferred to a nitrocellulose ﬁlter. Blocking
of the membrane was performed for 16 h at 4 °C with PBS (pH 7.4)
containing 5% (w/v) milk powder. Subsequently, the membrane was
incubated for 1 h with a 1:1000 dilution of anti-UPB1 antibody
(Sigma Aldrich B.V., Zwijndrecht, the Netherlands) in PBS with 5%
(w/v) milk powder, supplemented with 0.05% (v/v) Tween 20. The
membranes were washed three times (10 min each), once with PBS
containing 0.05% (v/v) Tween 20, 5% (w/v) milk powder and twice
with PBS containing 0.05% (v/v) Tween 20 and incubated for 1 h
with PBS containing 0.05% (v/v) Tween 20, 5% (w/v) milk powder
and a 1:2000 dilution of a polyclonal goat anti-rabbit secondary anti-
body conjugated to alkaline phosphatase (Santa Cruz Biotechnology,
Inc, Santa Cruz, CA). After rinsing the membrane three times (10 min
each), twice with PBS containing 0.05% (v/v) Tween 20 and once with
PBS, detection was performed with BCIP/NBT (Promega Benelux B.V.,
Leiden, The Netherlands).
2.6. Molecular cloning and site-directed mutagenesis
The coding sequence of the human UPB1 gene was re-cloned into
the pOPINF [25] expression vector (Oxford Protein Production Facility,
GenBankAccessionNo. EF372398), which includes the coding sequence
for a cleavable N-terminal 6×His-fusion tag. To this end, a sequence in-
dependent cloning approach (SLIC) was utilized with pSE420-ßUP as a
template. The DNA was ampliﬁed using high-ﬁdelity PfuTurbo DNApolymerase (Stratagene/Agilent) and the respective primers: forward:
5′-AAG TTC TGT TTC AGG GCC CGG CGG GCG CTG AGT GGA AGT C-3′;
reverse: 5′-ATG GTC TAG AAA GCT TTA CTC TTT CAC GAT GGT GGG
GCT G-3′ (italics: vector speciﬁc 5′ extensions; bold: stop codon).
pOPINF was digested with restriction enzymes HindIII and KpnI and
puriﬁed. Subsequently, 1.0 μg digested vector and 0.5 μg puriﬁed PCR
product were treated with 0.3 U of T4 DNA polymerase (NEB) at room
temperature for 30 min. The reaction was stopped by addition of dCTP
(1 mM). 25 ng of T4 DNA polymerase-treated vector and 11 ng of iden-
tically treated insert were incubated for 30 min at 37 °C and then trans-
formed into E. coli strain DH5α. Positive clones were identiﬁed by blue
andwhite screening. The correct insert was conﬁrmed by sequencing of
extracted plasmid DNA (Euroﬁns MWG Operon GmbH, Germany).
Point mutations were introduced by site-directed mutagenesis
using a modiﬁed QuikChange® protocol. Brieﬂy, plasmid DNA was am-
pliﬁed by PCR using 25 ng of wild-type plasmid DNA, 62.5 ng of the re-
spective mutagenesis primer pair, 1.25 U PfuTurbo DNA polymerase,
200 μM dNTPs and 1× PCR reaction buffer (25 μl ﬁnal volume).Mutation Primers Primer sequences
R326Q g977a 5′-cctgacagcagccagactcctgggctg-3′g977a_antisense 5′-cagcccaggagtctggctgctgtcagg-3′
T359M c1076t 5′-tgatgtctggaacttcaagatgatgggcaggtatga-3′c1076t_antisense 5′-tcatacctgcccatcatcttgaagttccagacatca-3′
L013S t38c 5′-tcgctggaggaatgctcggagaagcacctg-3′t38c_antisense 5′-caggtgcttctccgagcattcctccagcga-3′
S264R c792a 5′-ataggagcactcagagagtccctgtggcc-3′c792a_antisense 5′-ggccacagggactctctgagtgctcctat-3′
G235R g703a 5′-gtgaacatttgctacaggcggcaccaccc-3′g703a_antisense 5′-gggtggtgccgcctgtagcaaatgttcac-3′
R236W c706t 5′-catttgctacgggtggcaccaccccct-3′c706t_antisense 5′-agggggtggtgccacccgtagcaaatg-3′Following PCR with modiﬁed cycling parameters (95 °C 1 min;
15 cycles: 95 °C 1 min, 55 °C 1.5 min, 68 °C 6 min 44 s; 68 °C 20 min),
5 U DpnI was added to each reaction and incubated at 37 °C for 1 h.
The DNA was transformed into E. coli DH5α. The identity of the single
base substitutions was conﬁrmed by sequencing.2.7. Protein expression and puriﬁcation
Plasmids containing wild-type or mutant UPB1 were transformed
into E. coli strain C41(DE3)pRARE2. 1.5 l of culture broth (2.4% (w/
v) yeast extract, 1.2% (w/v) peptone, 0.1 M potassium phosphate
(pH ~7.2), 10 mM NaCl, 10 mM NH4Cl, 2 mM MgSO4) was inoculated
with 15 ml overnight culture in LB medium. All media were supple-
mented with 100 μg/ml carbenicillin and 35 μg/ml chloramphenicol.
Cells were grown under agitation at 37 °C until OD600 ~0.6 was
reached, cooled for ~30 min at 4 °C, and induced with IPTG (0.5 mM
ﬁnal concentration). After further incubation under agitation for
20 h at 25 °C, cells were harvested by centrifugation at 4000×g at
4 °C. The cells were washed with cold buffer containing 50 mM Na-
HEPES pH 7.4, 100 mM NaCl. After centrifugation the pellet was resus-
pended in cold cell lysis buffer (50 mM Na-HEPES pH 7.4, 300 mM
NaCl) supplemented with 50 μg/ml lysozyme, 10 μg/ml DNaseI and one
ROCHE “Complete®” EDTA-free protease inhibitor cocktail tablet, to a
ﬁnal volume of ~35 ml. Cells were disrupted by incubation at 25 °C for
20 min, followed by one freeze/thaw cycle and sonication. The superna-
tant resulting fromcentrifugation (40 min, 12,000×g, 4 °C)was stored at
−80 °C until further use.
The supernatant was supplemented with 25 mM imidazole and
500 μl Ni-NTA agarose afﬁnity matrix slurry (50% suspension, Qiagen)
per 50 ml lysate. After incubation for 1 h at 4 °C under rotation, the ly-
sate mixture was sedimented in a gravity ﬂow column and washed
with cell lysis buffer containing increasing imidazole concentrations
(25–75 mM). β-Ureidopropionase was eluted from the column using
a stepwise gradient of 100–500 mM imidazole in cell lysis buffer.
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centrated to 10 ml ﬁnal volume (Vivaspin 20, 10 kDa MW cutoff,
PES, Sartorius Stedim Biotech, Germany). The buffer was exchanged to
buffer A (20 mM Na-HEPES pH 7.4, 50 mM NaCl) using a Sephadex-
G25 desalting column (HiPrep™ 26/10, Pharmacia Biotech). Protein
containing fractions were collected and diluted to 50 ml with buffer A.
Cleavage of the N-terminal His-tag was achieved by addition of 1 μg
His-tagged 3C protease per 1 mg of target protein and incubation inFig. 2. Sequence conservation of the mutation sites in higher eukaryotic β-ureidopropionas
(Mm), rat (Rn), Drosophila melanogaster (Dm) and Arabidopsis thaliana (At) β-ureidopropion
mutation sites. Sequence conservation at these sites is indicated by gray background colori
positions at which strongly or weakly similar properties are conserved, respectively.the presence of 10 mMDTT for ~16 h at 4 °C. To remove uncleaved pro-
tein, the 3C protease and impurities, 500 μl Ni-NTA matrix slurry was
added to the solution and sedimented in a gravity ﬂow column. The
ﬂow-through was concentrated to 5 ml ﬁnal volume and applied to a
1 mlHiTrapQHP columnequilibratedwith buffer A.Wild-type andmu-
tant β-ureidopropionase were eluted with a linear gradient from 0 to
100% buffer B (20 mMNa-HEPES pH7.4, 800 mMNaCl) over 18 column
volumes with a ﬂow rate of 1 ml/min. β-Ureidopropionase-containinges. The alignment of the amino acid sequences of human (Hs), orangutan (Pp), mouse
ase reveals the strict conservation of all but one mutation sites. Bold font is used for the
ng. An asterisk (*) indicates fully conserved positions. Colon (:) and period (.) indicate
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~10 mg/ml, aliquoted, ﬂash frozen and stored at −80 °C until further
use.
2.8. Dynamic light scattering and circular dichroism spectroscopy
Dynamic light scattering (DLS) measurements were conducted
using a PD2000DLS plus Precision Dynamic Light Scattering detector
(Precision Detectors, Bellingham, MA, USA). The sample volume was
20 μl containing 2 mg/ml enzyme variant in 20 mM Na-HEPES buffer
pH 7.4, 100 mM NaCl. Measurements were carried out 150 times at
20 °C. Prior to measurement all samples were centrifuged for 15 min at
16,000×g and 4 °C and ﬁltered through a 0.1 μm ﬁlter to remove large
aggregates. For wild-type β-ureidopropionase, the equivalent measure-
ments were also performed at a protein concentration of 15 mg/ml.
Circular dichroism (CD) measurements were conducted on a
JASCO J-810 spectropolarimeter using a cuvette of 0.1 cm path length.
The samples contained0.2 mg/ml enzymevariant in 2 mMNa-HEPESpH
7.4, 10 mMNaCl. The spectra were recorded in the range of 190–260 nm
at 20 °C and corrected for background (buffer). Ten scans were averaged
without smoothing.
2.9. Native gel electrophoresis
Native polyacrylamide gel electrophoresis was performed using
4–20% Mini-Protean® TGX™ Precast Gels (BIO-RAD). The electrode
(running) buffer was 25 mM Tris, 192 mM glycine pH 8.3. The sample
buffer included 62.5 mM Tris pH 6.8, 40% glycerol, and 0.01% bromo-
phenol blue. Gels were run at 25 °C, and the voltage was kept con-
stant at 200 V.
2.10. Homology-based structural analysis
A homology model of human β-ureidopropionase was generated
using SWISSMODEL routines and the available crystal structure ofTable 1
Phenotype of 16 patients from 13 families with ß-ureidopropionase deﬁciencya.
Patient Origin Consanguinity Age
(years)
Gender Growth
retardation
Microceph
1. Japan − 0.5 F − −
2.1. Turkey + 0.8 M − −
2.2. 30 F − −
3.1. Egypt + Birth F − +
3.2. Birth M − +
3.3. 27 M unk unk
4. Egypt + 0.8 M − −
5. Pakistan + 2.0 F + ++
6. China − 1.1 M + +
7. Germany − 0.9 F − −
8. China 3.0 M + −
9. Turkey + 5.3 F − −
10. Turkey + 3.0 F + −
11. Germany − 0.9 M − +
12. ‘African’ − 1.0 F − −
13. Australia − 1.0 M − −
Total 26% (4/15) 33% (5/15)
a − absent; + present, mild; ++ present, severe; unk unknown.
b CD, cortical dysplasia; A, atrophia cerebri; DM, delayed myelination; VH, vermis hypop
c F, focal seizures; I, infantile spasms; TC, tonic–clonic seizures; SAS, single atonic seizure
d 1Progressive mood changes [32]; 3.2facial morphology: prominent metopic suture, do
unrelated to seizure activity; demise at 18 days; 4recurrent attacks of vomiting and severe
marked hyperopia, pale optic nerves; normal ERG and VEP; 6nephrotic syndrome at 1.9 y
11 months bout of fever and diarrhea, development of uncontrollable seizures and cerebral
including nystagmus, tremor; optic atrophy and at 2.3 year abnormal retina pigmentation, fr
[12]; 11at 5 m polytopic myoclonic jerks; no visual contact, mild optic atrophy [12,48]; 12bro
extrophy, biﬁd phallus, biﬁd scrotum, duplicated distal colon, anal atresia [13].
e Hypertonia.β-ureidopropionase from D. melanogaster (PDB ID: 2vhi and 2vhh)
[18]. The single amino acid exchanges caused by the point mutations
were manually introduced to the homology model using WinCoot
[26], choosing energetically preferred side chain conformations that
cause the least steric clashes and interact optimallywith surrounding res-
idues. A model of a (putative) tetramer of human β-ureidopropionase
was constructed from monomeric homology models by superposition
onto the respective subunits of DmβUP inWinCoot. The ﬁgures showing
the pointmutation sites and their environmentwere generated using the
program PyMOL (DeLano, W.L. The PyMOL Molecular Graphics System
(2002), url: http://www.pymol.org). The sequences shown in Fig. 2
were aligned with CLUSTAL W [27].
3. Results
3.1. Clinical phenotype
The clinical features of all 16 known ß-ureidopropionase deﬁcient
patients are shown in Table 1. The sex ratio was equal. Most patients
were referred in the ﬁrst two years of life; in two families an adult
was only recognized after diagnosis in a relative. The most common
ﬁndings were an abnormal MRI, seizures, intellectual disabilities
and hypotonia or hypertonia (in 85%, 60%, 57% and 53% of the pa-
tients, respectively). MRI ﬁndings varied from agenesis of the callosal
body and vermis hypoplasia with brain stem hypoplasia to delayed
myelination and general brain atrophy. Two siblings had cortical dys-
plasia. In four patients convulsions occurred as infantile spasms,
which changed into focal and tonic–clonic seizures in one of them.
Three other patients also had focal epilepsy. Growth retardation, mi-
crocephaly and autism were observed less frequently. Three patients
developed opticus atrophy with a decreased vision. One other patient
had bilateral microphthalmia and, likely, secondary optical atrophy.
Two patients showed a progression in symptomatology, especially
with respect to their neurological symptoms. Phenotypic variability
of ß-ureidopropionase deﬁciency was demonstrated in one family inaly Intellectual
disability
Abnormal MRIb Seizuresc Hypotonia Autism Otherd
+ − I − + 1
− unk F + −
− unk − − −
− CD I − − 3.2
unk CD I, F, TC −e unk
unk unk unk unk unk
+ A + ++ unk 4
++ A, CH − ++ + 5
++ DM − − − 6
− A F ++ − 7
+ − − − −
++ A, VA, BH, DM,
CH
− ++ unk 9
+ DM I − − 10
++ A, SH F, TC ++ unk 11
− − SAS −e unk 12
− − − − unk 13
57% (8/14) 85% (11/13) 60%
(9/15)
53%
(8/15)
22%
(2/9)
lasia; BH, brainstem hypoplasia; CH, callosal body hypoplasia; SH, subdural hematoma.
(30 min).
licocephaly, downward slanted palpebral ﬁssures; recurrent episodes of desaturation
dehydration, respiratory infections, demise at 13 months; 5bilateral microphthalmia,
ears; 7initial development (until 11 months) normal; transient cerebral blindness. At
edema, followed by brain atrophy; 9from birth on dystonia, abnormal eye movements
om 11 m on scoliosis, no speech [34,47]; 10possibly hearing deﬁcit; severe speech delay
ther died at 9 m after number of convulsive crises (no further information) [12]; 13bladder
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notype did not lead to overt symptoms in the mother of the patient.3.2. Biochemical phenotype
As part of a selective screening program for inborn errors, the py-
rimidine bases, uracil and thymine, and their degradation products
were analyzed in urine, plasma and CSF samples. Urine and plasma
samples of the patients showed strongly elevated levels of N-carbamyl-
ß-alanine and N-carbamyl-ß-aminoisobutyric acid and moderately ele-
vated levels of dihydrouracil anddihydrothymine (Fig. 3). Themean con-
centration of uracil (22.4±16.1 μmol/mmol creatinine), thymine (3.0±
2.1 μM μmol/mmol creatinine), dihydrouracil (58±36 μmol/mmol cre-
atinine) and dihydrothymine (134±67 μmol/mmol creatinine) was
2-fold, 6-fold, 9-fold and 43-fold, respectively, higher compared to the
mean concentration in urineof controls. In contrast, themean concentra-
tions of N-carbamyl-ß-alanine (755±361 μmol/mmol creatinine) and
N-carbamyl-ß-aminoisobutyric acid (533±214 μmol/mmol creatinine)
were 69-fold and 269-fold, respectively, higher compared to the meanFig. 3. Concentrations of N-carbamyl-ß-amino acids and dihydropyrimidines in ß-ureidopro
ß-alanine (NCß-Ala) and N-carbamyl-ß-aminoisobutyric acid (NCß-AIB) and panel b show
plasma levels of the N-carbamyl-ß-amino acids and dihydropyrimidines are shown in panels
to the 75th percentile, 25th percentile and 50th percentile, respectively. The whiskers on tconcentration observed in urine of controls. In plasma, the mean con-
centrations of N-carbamyl-ß-alanine (17±6 μM) and N-carbamyl-ß-
aminoisobutyric acid (24±10 μM) concentrations were 91-fold and
178-fold, respectively, higher compared to the mean concentration ob-
served in controls. In ß-ureidopropionase deﬁcient patients, a strong
correlation existed between urinary concentration of N-carbamyl-ß-
alanine and N-carbamyl-ß-aminoisobutyric acid (R2=0.80, P=0.0004).
A similar correlation existed between the N-carbamyl-ß-alanine and N-
carbamyl-ß-aminoisobutyric acid concentration in plasma (R2=
0.82, P=0.001). Thus, the observed N-carbamyl-ß-amino aciduria in
these patients strongly suggested ß-ureidopropionase deﬁciency.3.3. Genotype
Analysis of the genomic sequences of exons 1–11 of UPB1 includ-
ing their ﬂanking intronic sequences in the hitherto uncharacterized
patients showed two previously described splice-site mutations (c.105-
2A>Gand c.917-1G>A) [12] and7novelmutations, including 6missense
mutations and one splice-site mutation (Table 2). Homozygosity for onepionase deﬁcient patients and controls. Panel a shows the urinary levels of N-carbamyl-
s the concentrations of dihydrouracil (DHU) and dihydrothymine (DHT) in urine. The
c and d, respectively. The top, bottom and line through the middle of a box correspond
he bottom extend from the 2.5th percentile and top 97.5th percentile.
Table 2
Results of mutation analysis in 11 patients with ß-ureidopropionase deﬁciency.
Patient Genotype Effect Location
1. c.[977G>A]+[977G>A] p.[R326Q]+[R326Q] Ex 9
2.1 c.[1076C>T]+[1076C>T] p.[T359M]+[T359M] Ex 10
2.2 c.[1076C>T]+[1076C>T] p.[T359M]+[T359M] Ex 10
3.1 c.[105-2A>G]+[105-2A>G] Splicing Intron 1
3.2a
3.3 c.[105-2A>G]+[105-2A>G] Splicing Intron 1
4.lb c.[38T>C]+[38T>C] p.[L13S]+[L13S] Ex 1
5. c.[792C>A]+[873+1G>A] p.[S264R]+splicing Ex 7, intron 7
6. c.[977G>A]+[977G>A] p.[R326Q]+[R326Q] Ex 9
7. c.[703G>A]+[917-1G>A] p.[G235R]+splicing Ex 6, intron 8
8. c.[706C>T]+[792C>A] p.[R236W]+[S264R] Ex 6, Ex 7
a No DNA available.
b No DNA available, parents of the deceased patient were heterozygous for the
c.[38T>C] mutation.
Fig. 5. ß-Ureidopropionase activity and immunoblot analysis of wild-type and mutant
ß-ureidopropionases expressed in E. coli as well as that of human liver. The results rep-
resent the mean of three independent measurements, the error bar represents 1 SD.
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tations c.792C>A and c.977G>A were each present in two unrelated pa-
tients. Fig. 4 shows the distribution of UPB1 mutations over the exons.
Mutations were found to occur in all exons except exons 3–5.
3.4. Functional analysis of mutant ß-ureidopropionase enzymes
To investigate the effect of the 6 missense mutations on the activ-
ity of ß-ureidopropionase, the mutations were introduced into a
pSE420-ßUP vector using the megaprimer technique and expressed in
E. coli. No endogenous ß-ureidopropionase activity (b0.3 nmol/mg/h)
could be detected in the E. coli strain used for the expression of the con-
structs. Introduction of wild-type ß-ureidopropionase construct in-
creased ß-ureidopropionase activity more than 1000-fold above the
background level. Expression of ß-ureidopropionase constructs con-
taining the mutations p.L13S, p.G235R, p.R236W, p.S264R, p.R326Q
and p.T359M yielded no or signiﬁcantly decreased ß-ureidopropionase
activity (Fig. 5).
To exclude the possibility that the lack of ß-ureidopropionase activ-
ity was the result of an inability to produce themutant protein in E. coli,
the expression levels were analyzed by immunoblotting. Fig. 5 shows
that the mutant proteins were expressed in comparable amounts as
the wild-type protein. Thus, the lack of ß-ureidopropionase activity of
mutant ß-ureidopropionase enzymes in E. coli is not due to rapid degra-
dation of the various mutant ß-ureidopropionase proteins in the E. coli
supernatants. Nevertheless, it does not give sufﬁcient evidence as to
whether the mutant proteins are stably folded.
To enable rapid puriﬁcation and thus further analysis of the mutant
enzymes, the human UPB1 gene was re-cloned into a vector (pOPINF)
fusing a His-tag at the N-terminus of the protein. The subsequent intro-
duction of single point mutations using the QuikChange® method was
straightforward for all but one of the sites. Several attempts to mutate
the site giving rise to p.R326Q each time resulted in ampliﬁcation of in-
complete vectors for yet unknown reasons. No sufﬁcient expression of
soluble protein was observed for p.G325R preventing further puriﬁca-
tion. The amounts of puriﬁed protein obtained from the same culture
volume ranked according to p.R236W b p.S264R b p.L13S b wild-type b
p.T359M, giving a crude estimate of the relative expression levels forFig. 4. Genomic organization and mutation analysis of the UPB1 gene. UPB1 consists of 11 ex
tions identiﬁed in ß-ureidopropionase deﬁcient patients are indicated, numbers correspondthe soluble proteins. p.R236Wcould be puriﬁed to only ~80%homogene-
ity, due to lower expression levels, all other enzyme variants to >95%
homogeneity. The β-ureidopropionase activity of the wild-type and pu-
riﬁed mutant proteins is given in Table 3.
CD spectra were recorded to investigate whether the reduced en-
zymatic activity of themutant enzymeswas caused by folding defects.
The CD spectra of p.L13S and p.S264R were nearly identical to that of
wild-type β-ureidopropionase in the far UV range, indicating no or lit-
tle disturbance of the secondary structure by the single amino acid ex-
changes (Fig. 1S, Supplementary data). In contrast, while still clearly
indicating that the proteins were folded, the spectra of p.R236W and
in particular p.T359M showed larger deviations from the wild-type
β-ureidopropionase spectrum.
Size exclusion chromatography experiments originally included in
the puriﬁcation procedure for wild-type β-ureidopropionase did not
indicate the presence of large amounts of protein aggregates or of
an oligomer equilibrium. These experiments were usually performed
at lower protein concentrations (b1 mg/ml), and the retention time
of the single protein peak with β-ureidopropionase activity would
correspond to a monomeric or dimeric state of the enzyme.
In contrast, the dynamic light scattering experiments performed
at a protein concentration of 2 mg/ml revealed that wild-type as
well as mutant β-ureidopropionase solutions showed a high degree
of polydispersity likely to be caused by the concomitant presence of
different oligomeric states (Fig. 2S, Supplementary data). In addition,
the observation of very large hydrodynamic radii indicated that all of
the puriﬁed β-ureidopropionase proteins have a tendency to aggre-
gate — although visible precipitation was absent. Both observed phe-
nomena together led to a large variation between the ﬁve repeated
measurements per protein variant and prevented an accurate estimation
of the predominant oligomeric state. Nevertheless, while for wild-type
β-ureidopropionase hydrodynamic radii of 4.0–5.5 nm (average 4.9 nm)
were most often observed, possibly corresponding to homodimeric to
homohexameric assemblies, smaller average radii were measured forons encoding an open reading frame of 1152 bp (depicted in gray). The various muta-
to the cDNA position.
Table 3
Activity of puriﬁed wild-type and mutant ß-ureidopropionases.
Enzyme ß-Ureidopropionase activity (nmol/mg/h)
Wild-type 16,919±638
p.R236W n.d. (b9.5 nmol/mg/h)
p.T359M n.d. (b4.9 nmol/mg/h)
p.L13S 1003±110
p.S264R 3346±51
n.d., not detectable.
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at the sameprotein concentration. It indicates a shift of a potential equi-
librium of oligomeric states towards the lower molecular weight
species, which is conﬁrmed by native gel electrophoresis (Fig. 3S, Sup-
plementary data). p.L13S and p.T359M appear as a single broad band
of lower molecular weight than the sharper double band observed for
thewild-type enzyme. Native gel analysis of p.S264R reveals two distinct
double bands, onewith approximately the same and one of lowermolec-
ular weight than that observed for the wild-type β-ureidopropionase. In
contrast, a larger average hydrodynamic radius (8.3 nm) was observed
for p.R236W. This may be attributed to the presence of a contaminating
protein since analysis by native gel electrophoresis does not give any in-
dication for a stabilization of higher oligomeric states or increased aggre-
gation. Instead, the predominant state of this mutant is smaller in size
than that of the wild-type enzyme. DLS measurements performed for
wild-type β-ureidopropionase at a protein concentration of 15 mg/ml
led to a slight increase in observed hydrodynamic radius (5.3 nm) and
polydispersity.
3.5. Structural effects of ß-ureidopropionase mutations
To further investigate the effects of the missense mutations iden-
tiﬁed in the human UPB1 gene, a homology model of the gene product
was generated using the 3D structure of ß-ureidopropionase from
D. melanogaster (DmβUP) (Fig. 6a) [18]. The 63% sequence identity
shared by both enzymes indicates that the αββα-sandwich core of the
subunit is structurally well conserved while peripheral structure ele-
ments could show deviations. It is not yet known whether the physio-
logically relevant oligomeric assembly of human ß-ureidopropionase
mirrors that of DmβUP. Hence, the consequences ofmutations affecting
surfaces buried upon formation of oligomers larger than a dimer areFig. 6. The crystal structure of DmβUP and location of the mutation sites. (a) Schematic vie
differently. (b) Schematic view of a dimeric unit. For one of the subunits β-strands are dep
The mutation sites identiﬁed for human β-ureidopropionase are indicated by space-ﬁll mo
blue for the other. The labels state ﬁrst the site in the human enzyme, then the correspon
the active site cysteines (C233 in human β-ureidopropionase, C234 in DmβUP) colored yeldifﬁcult to predict if their assembly does not engage the same subunit
surfaces as seen for DmβUP.
Interestingly, all six point mutations affect residues that are well
(R326) or strictly (L13, G235, R236, S264, T359) conserved in higher
eukaryotic ß-ureidopropionases (Fig. 2) and cluster at or close to the
subunit surface that becomes buried upon dimerization (Fig. 6b). Only
three mutations, G235R, R236W and S264R, lead to amino acid ex-
changes in the active site and are, therefore, likely to have also direct ef-
fects on substrate binding and catalysis.
G235 is close to the catalytically crucial cysteine (C233) that per-
forms the nucleophilic attack on the substrate resulting in the cova-
lent acyl-enzyme complex [18]. The mutation G235R introduces a
large amino acid side chain for which there is no space available at
this location. The larger structural rearrangements in the active site
cavity required to prevent clashes with surrounding residues are
expected to lead to enzyme inactivity and misfolding and defects in
oligomerization (Fig. 7a). The inability to obtain signiﬁcant expres-
sion of soluble protein for this mutant supports this conclusion.
R236 is part of the active site and has a putative role in binding the
carboxyl group of the substrate (Fig. 7b). The side chain of the trypto-
phan introduced by the mutation R236W is much more rigid and hy-
drophobic and does not carry a charge at physiological pH. Therefore,
the shape and charge state of the active site would be signiﬁcantly al-
tered by the mutation, preventing substrate binding and rendering
the enzyme inactive. Furthermore, a multitude of close contacts to
nearby residues are likely to cause protein misfolding. The clear but
relatively small changes in the CD spectrum of p.R236W indicate
that misfolding is locally restricted, most likely to the direct neighbor-
hood of the mutation site. Nevertheless, such smaller structural devi-
ations could potentially impair the formation of higher oligomers due
to the proximity of the mutation site to subunit surfaces that are in
DmβAS involved in dimerization and tetramerization.
The mutation S264R abolishes the hydrogen bond to Y314, which
may be important for structural ﬁxation of a residue stretch that is in-
volved in shaping the entrance to the active site (Fig. 7c). Most steric
clashes with adjacent residues can be avoided if the introduced argi-
nine side chain is oriented towards V202, F205, I260, W354 (from a
neighboring subunit) and T259. However, this would obstruct the
tunnel leading from the protein surface to the active site and thereby
hinder substrate binding, and also be energetically unfavorable due to
the placement of a hydrophilic and charged group in a hydrophobic
environment. Based on the homology modeling, mutation-inducedw of the homooctameric DmβUP in cartoon representation with each subunit colored
icted in brown and helices in salmon; the other subunit in the dimer is colored cyan.
dels of the corresponding amino acid side chain, shown in red for one subunit and in
ding DmβUP site. The location of the active site is indicated by a space-ﬁll model of
low for both subunits.
Fig. 7. The environment of the mutation sites G235R, R236W and S264R in the homology model of human β-ureidopropionase. The dimeric model of the human β-
ureidopropionase is shown in cartoon representation with different colors for distinct subunits. Stick models of the side chains introduced by the point mutations are shown
with carbon atoms in magenta. The conformer causing the least clashes with surrounding residues was chosen. The replaced native side chains are shown with yellow carbon
atoms and thinner sticks. The catalytic cysteine is shown in ball-and-stick with yellow carbon atoms. Further residues discussed in the text or within van-der-Waals radius of
the mutation site are shown with carbon atoms in white for the subunit depicted in salmon, and in light blue for the (blue) partner subunit in the dimer (labeled with an asterisk).
Amino acid side chains of DmβUP that are either not conserved in human β-ureidopropionase, differently oriented or involved in different interactions are shown as stick models in
green. In these cases, labels name ﬁrst the residue present in human β-ureidopropionase, followed by the DmβUP residue in brackets. Hydrogen bonds are indicated by dotted black
lines, and surfaces outlining the dimensions of the active site cavity and the entrance area are shown in light gray. (a) Close-up stereo view of the G235R mutation site. (b) Close-up
stereo view of the R236Wmutation site. C233, K196 and E119 form the catalytic triad present in all nitrilase-like enzymes and interact with the carbamoyl moiety of the substrate.
This triad is in most but not all branches of the nitrilase superfamily extended to a tetrad by a conserved glutamate [27] corresponding to E207 in human β-ureidopropionase. R236,
T259 and H237 are thought to be important for the recognition and binding of carboxyl group of the substrate [18]. (c) Close-up stereo view of the S264R mutation site.
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ably also affect dimer or higher oligomer assembly, since S264 is located
at the interface between monomers. Although differences in the far-UV
CD spectra betweenp.S264R andwild-typeβ-ureidopropionase aremin-
imal, the decrease in hydrodynamic radius for p.S264R and the appear-
ance of an additional band for a lower molecular weight species in the
native gel would support the latter conclusion.
L13 belongs to the ~65 amino acid extension at the N-terminus
that is unique to the ß-ureidopropionases branch of the nitrilase
superfamily. It prohibits higher oligomer assembly modes that are
typical for members of other branches but distinctly different from
that of DmβUP. The L13 side chain contributes to the densely packed
hydrophobic interaction surface between the subunits of a dimer
(Fig. 8a). The non-conservative mutation to the smaller serine leads to
signiﬁcant gaps in the hydrophobic core and introduces a polar side
chain in a non-polar environment, which may cause a hydrophobiccollapse of the 4-helical bundle and signiﬁcantly destabilize the mono-
mer–monomer interface. However, the CD spectrum of p.L13S is basi-
cally unaltered, arguing against extensive changes of the secondary
and tertiary structures of the mutant protein. The spatial distance be-
tween mutation and active site also excludes direct interference of the
amino acid exchange with substrate binding or the catalytic residues.
Another explanation for the signiﬁcant decrease in enzymatic activity
of p.L13S is its potential dependence on proper oligomer assembly,
which is affected by the mutation.
The effects of the R326Q exchange are difﬁcult to predict. In DmβUP,
the corresponding R327 is located near the dimer interface without
being directly involved in contacts with the partner subunit (Fig. 8b).
Its side chain forms hydrogen bonds to T328 and S330, of which the lat-
ter is not conserved in human ß-ureidopropionase due to the replace-
ment of S330 by a glycine. The mutation R326Q is likely to bring the
introduced glutamine carboxamide group in close contacts with either
Fig. 8. The environment of the mutation sites L13S, R326Q and T359M in the homology model of human β-ureidopropionase. Depicted residues are colored, represented and labeled
as in Fig. 2. (a) Close-up stereo view of the L13S mutation site. Van-der-Waals surfaces of residues near the mutation site are depicted in light gray and blue to visualize the tight
packing of the hydrophobic side chains. In one subunit the van-der-Waals surface of L13 is shown (yellow), in the other the corresponding surface of S13 is introduced by the mu-
tation (magenta). (b) Close-up stereo view of the R326Q mutation site. (c) Close-up stereo view of the T359M mutation site. M212 belonging to another dimeric unit (shown in
orange) is labeled with a hash. Sequence differences between human ß-ureidopropionase and DmβUP near the mutation site are here indicated by green spheres for conservative
exchanges and red spheres for non-conservative exchanges. (d) Stereo view of the location of the T359M in a tetrameric homology model of human β-ureidopropionase. One sub-
unit is shown in cartoon representation, with β-strands in brown and helices in salmon. The mutation site is indicated by the space-ﬁll model of the corresponding side chain in red,
the location of the active site by a space-ﬁll model of C233 in yellow. The partner subunit in the dimer and both subunits of the other dimer are shown in surface representation in
cyan and light gray, respectively.
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T327 as well as stacking interactions with Y318. Thus, a glutamine
may only partly or not at all fulﬁll the structural role of R326 and there-
by affect proper dimer assembly. Puriﬁcation and further characteriza-
tion of the mutant enzyme are required for a precise determination of
the functional and structural consequences of the amino acid exchange.Fig. 8c and d depict the structural context of the mutation site
T359 in the homology model of a (putative) tetramer of human ß-
ureidopropionase, which was constructed assuming that its assembly
mode is equivalent to that of DmβUP. T359 precedes the C-terminal
helix that interacts with its counterpart from the dimer mate in an
interlocking manner. It is in direct contact to residues from the partner
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hydrogen bond may be formed with N355. T359 is also spatially close
to residues from another dimer unit, in particular M212. The T359M
mutation introduces a larger and hydrophobic side chain, abolishing
the hydrogen bond to N355 and causing close contacts with E213,
I199 and R201 from the dimer mate and with M212 from another
dimer. Thus, also the T359M point mutation is likely to lead to a desta-
bilization of subunit interfaces within the dimer or between dimeric
units in potentially existing larger oligomers, which is supported by
the results of DLS measurements and native gel electrophoresis. Devia-
tions from wild-type β-ureidopropionase in the CD spectrum indicate
structural changes that may range from a simple detachment of the C-
terminal helix and tail to dissociation of dimeric units. The complete
loss of enzymatic activity upon mutation of a solvent-exposed residue
distant from the active site would rather speak for the latter.
4. Discussion
ß-Ureidopropionase deﬁciency is an inborn error of the pyrimidine
degradation pathway, affecting the cleavage of N-carbamyl-ß-alanine
and N-carbamyl-ß-aminoisobutyric acid. Patients with complete ß-
ureidopropionase deﬁciency presented with strongly elevated levels
of the N-carbamyl-ß-amino acids in urine and plasma. It has been
shown that N-carbamyl-ß-alanine and N-carbamyl-ß-aminoisobutyric
acid are weak inhibitors of dihydropyrimidinase [28] which might ex-
plain the moderately increased levels of dihydrouracil and dihydrothy-
mine in the patients. However, the mean urinary concentration of
dihydrouracil and dihydrothymine and the pyrimidine bases uracil
and thymine are 5.5-fold, 1.5-fold, 2.7-fold and 15-fold, respectively,
lower in patients with a ß-ureidopropionase deﬁciency compared to
that observed in patients with a dihydropyrimidinase deﬁciency [10].
The most frequently observed clinical manifestations in the present
study group were mainly neurological: MRI abnormalities, seizures, in-
tellectual disabilities and abnormal tonus regulation. Although neuro-
logical abnormalities are also observed in patients with a DPD or
dihydropyrimidinase deﬁciency [9–11,29], the clinical presentation of
the patients with a ß-ureidopropionase deﬁciency seems to be more
severe. The high frequency of gastrointestinal problems, which was ap-
parent in dihydropyrimidinase deﬁcient patients, was not observed in
patients with ß-ureidopropionase deﬁciency. The frequent occurrence
of optic nerve hyoplasia going along with visual disturbances is not
mirrored in the eye ﬁndings in other pyrimidine disturbances [9,10].
Malformations elsewhere were uncommon. It should be mentioned
that the present phenotype may represent a bias, due to the selection
of patients of whom samples were submitted. The unexpected ﬁnding
of a pyrimidine metabolism disturbance in patients with Miller syn-
drome characterized by missing ﬁngers and toes, and markedly abnor-
mal face but no neurological problems, detected by sequencing all
coding parts of the whole genome, showed that it is possible that pa-
tients with a completely different phenotype may have a pyrimidine
metabolism disturbance [30]. Recently, 4 asymptomatic neonates with
a putative ß-ureidopropionase deﬁciency were detected during a pilot
study of newborn urine screening and two infants during high risk
screening in Japan [31,32]. Thus, although these Japanese patients
have not been conﬁrmed molecularly, the identiﬁcation of individuals
with biochemically complete ß-ureidopropionase deﬁciency without
any clinical manifestations and the marked intrafamilial variability in
phenotype, indicate that additional (epi)genetic and environmental
factors are likely to be involved.
The pathogenesis underlying the various clinical manifestations re-
mains as yet unknown. Biochemically, patients with a deﬁciency in
one of the three enzymes of the pyrimidine degradation pathway
show moderately decreased levels of ß-alanine and strongly decreased
levels of ß-aminoisobutyric acid [3,12,33]. Treatment of a patient with
ß-ureidopropionase deﬁciency with ß-alanine for over 1.5 years did
not result in a clinical improvement [34]. ß-Aminoisobutyric acid isnot only a partial agonist of the glycine receptor [8] but it also increases
the secretion of leptin and stimulates fatty acid oxidation [6,7]. Leptin it-
self has been shown to have neuroprotective, cognitive and anticonvul-
sant effects [35–37]. Thus, it is conceivable that the altered homeostasis
of ß-aminoisobutyric acid in patientswithß-ureidopropionase deﬁcien-
cymight affect leptin levels and fatty acid oxidation and contribute to the
development of intellectual disability and hypotonia in the patients. Nev-
ertheless, the fact that the clinical presentation of patients with a ß-urei-
dopropionase deﬁciency seems to be different compared to that observed
for patients with a DPD and dihydropyrimidinase deﬁciency, suggests
that additional factors are likely to be involved.
In this respect, it has been suggested that N-carbamyl-ß-alanine,
one of the accumulating substrates, might function as an endogenous
neurotoxin [38] as high concentrations of N-carbamyl-ß-alanine
inhibited the mitochondrial energy metabolism which was accompa-
nied by the induction of oxidative stress. Previously, however, we
showed that the concentrations of N-carbamyl-ß-alanine were only
marginally elevated in CSF of patients, arguing against a direct role
of N-carbamyl-ß-alanine in the neuropathology [12]. Furthermore,
two patients (2.2 and 3.2) who presented with low urinary levels of
N-carbamyl-ß-amino acids were asymptomatic and severely affected,
respectively.
Mutation analysis of UPB1 showed 7 novel mutations, including 6
missense mutations and one splice-site mutation. The c.873+1G>A
mutation is located in a conserved splice-donor site and most likely
leads to alternative splicing of the pre-mRNA and thus to a non-
functional protein. The two previously indentiﬁed splice-site muta-
tions c.105-2A>G and 917-1G>A led to a variety of alternative
splice-variants, with deletions of a single or several exons [39]. Heter-
ologous expression of 6 mutant enzymes in E. coli showed that all
missense mutations yielded mutant ß-ureidopropionase proteins
with no or signiﬁcantly decreased activity.
Recently, the crystal structure of D. melanogaster (DmβUP) has
been determined [18]. Its subunit shows signiﬁcant similarity to that
of other enzymes of the nitrilase superfamily [21] and comprises a
central β-sandwich ﬂanked on both sides by several α-helices.
However, compared to other nitrilase-like enzymes the sequence of
ß-ureidopropionases is extended at the N-terminus by ~65 amino
acids, which in DmβUP form three α-helices and the ﬁrst strand of
one of the β-sheets. Upon dimerization, the ﬁrst two helices interact
with their counterparts to form a 4-helical bundle located on a
solvent-exposed face of the dimer. Besides this extra contribution to
the monomer–monomer interface, the dimer is always assembled in
an identical fashion in nitrilase-like enzymes of known structure, oc-
cluding the same face of the β-sandwich. It is therefore likely that
human β-ureidopropionase uses a very similar assembly mode. Analy-
sis of the three-dimensional structure showed that the mutations
G235R, R236W and S264R lead to amino acid exchanges in the active
site and, therefore, likely affect substrate binding and catalysis directly.
The other three mutations L13S, R326Q and T359M did not affect resi-
dues located in or near the active site. The inactivity of the correspond-
ing mutant enzymes might be caused by folding defects and structural
instability. Additionally, all mutation sites are located near surfaces
that are expected to become buried upon formation of higher oligomer-
ization states, and stabilization of lower molecular weight species has
been observed for all further investigatedmutant enzymes. Thus, anoth-
er explanation for the abolished or decreased enzymatic activity of L13S,
R326Q and T359Mmay exist if ß-ureidopropionase is allosterically regu-
lated by ligand-induced changes in oligomerization state as described for
the enzyme from rat liver and for somebacterial nitrilases [15,40–42]. For
these enzymes, association to larger oligomerswas accompaniedwith in-
creased activity, while the smallest assemblies (most likely the dimers)
were catalytically inactive. Analysis of the crystal structure of DmßUP
revealed a possiblemechanism for such an allosteric regulation, involving
the structural stabilization and ﬁxation of three loops forming the en-
trance to and part of the active site upon interaction of dimeric units
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prevent proper subunit association to higher oligomers would be in ac-
cordance with such a model.
The three enzymes of the pyrimidine degradation pathway are not
only responsible for the catabolism of the naturally occurring bases
uracil and thymine, but also of the widely used chemotherapeutic
agent 5-ﬂuorouracil. In this light, deﬁciencies of DPD and dihydropyr-
imidinase have been associatedwith severe toxicity after the administra-
tion of 5-ﬂuorouracil [43–45]. The identiﬁcation of a healthy individual
showing altered catabolismof uracil due to heterozygosity for amutation
in UPB1 suggests that also patients with a ß-ureidopropionase deﬁciency
might be at risk of developing 5-ﬂuorouracil toxicity [46]. In addition, the
ﬁnding of 2 mutations in multiple ß-ureidopropionase patients of
different nationalities may indicate that a ß-ureidopropionase deﬁ-
ciency might not be as rare as generally considered. The prevalence of
a ß-ureidopropionase deﬁciency in Japan has been estimated to be 1
in 6000 [32]. The present results should facilitate the identiﬁcation of
further individuals with ß-ureidopropionase deﬁciency.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2012.04.001.
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